During the study, participants will receive treatment for up to 104 weeks. The maximum daily dose of ALXN2030 that may be given is 450 milligrams. The study will examine whether the medication can help resolve the signs of rejection seen in kidney tissue samples, improve kidney function as measured by a blood test called estimated glomerular filtration rate, and reduce the activity of the rejection process. Before starting the study medication, all participants must be vaccinated against certain bacterial infections including meningococcal infection, pneumococcal infection, and Haemophilus influenzae type B infection, as the study medication may affect the immune system.

Throughout the study, doctors will monitor participants for any side effects or unwanted reactions to the treatment. They will also measure the amount of ALXN2030 in the blood over time and check if the body develops any antibodies against the study medication. The study will also track changes in certain proteins and immune system activity in the blood to understand how the medication works in the body. Kidney tissue samples will be taken at specific times during the study to assess whether the rejection process has improved or resolved.

During the study, patients will receive belimumab injections for four weeks. The medication works by affecting certain immune cells called memory B-cells, which are responsible for producing antibodies. By influencing these cells, the medication may help them move from areas like lymph nodes into the bloodstream, where they can be tested more accurately. Doctors will take blood samples before treatment starts, during the four weeks of treatment, and at several time points afterward up to 36 weeks. These blood samples will be analyzed to see which specific tissue types the patient’s immune system is reacting against and whether the pattern of antibodies changes over time.

The study will measure several things, including how many specific tissue type antibodies are found in the blood before and after treatment, whether the list of unacceptable tissue types for transplant can be reduced, and whether this improves the chances of finding a matching donor. For patients who receive a transplant after participating in the study, doctors will track whether the transplanted kidney is rejected, whether new antibodies develop, and whether the kidney continues to work properly. The study will also monitor the safety of the treatment by recording any side effects that occur during and after the four weeks of belimumab treatment.

The purpose of this study is to evaluate how effective these umbilical cord cells are in improving kidney function over a period of 24 months in patients with cABMR. Participants in the study will receive injections of these cells and will be monitored for changes in their kidney function. The study will also look at the safety of the cell injections and how they affect the body. Participants will have regular check-ups to assess their kidney function and overall health. The study will also compare the results with those of patients who receive a placebo, which is a substance with no active treatment.

Throughout the study, various health indicators will be measured, such as kidney function, protein levels in urine, and the presence of specific antibodies that can affect the kidney. The study aims to provide valuable information on whether this new cell therapy can help improve outcomes for patients experiencing chronic rejection of their transplanted kidney. The trial is expected to run until 2028, with the goal of finding a more effective treatment for this challenging condition.

The purpose of the study is to evaluate how effective and safe BIVV020 is in managing transplant rejection. Participants in the study will be divided into two groups. One group will receive the treatment to see if it can prevent rejection from happening, while the other group will receive it to treat active rejection. The treatment is given as a solution for injection under the skin, and the study will monitor participants over a period of time to assess the treatment’s effects.

Throughout the study, researchers will collect information on how well the treatment works, any side effects, and how the body processes the medication. This will help determine if BIVV020 is a viable option for managing transplant rejection in kidney transplant recipients. Participants will be closely monitored to ensure their safety and to gather comprehensive data on the treatment’s impact.

The purpose of the study is to evaluate the safety and tolerability of Efgartigimod in people who have experienced antibody-mediated rejection after a kidney transplant. Participants in the study will receive either Efgartigimod or a placebo, which looks like the treatment but does not contain the active medication. The study will be conducted over a period of time, during which participants will receive regular injections and attend follow-up visits to monitor their health and the effects of the treatment.

Throughout the study, various health assessments will be conducted, including checking for any side effects, monitoring kidney function, and measuring levels of certain proteins in the blood. The study aims to gather information on how well Efgartigimod works in managing antibody-mediated rejection and its overall impact on the health of kidney transplant recipients. Participants will be closely monitored by healthcare professionals to ensure their safety and well-being during the trial.